Final model of multiple logistic regression identifying children/adolescent, mother/primary caregivers and family associated factors with mental health service use (N = 1,721).

<p>Final model of multiple logistic regression identifying children/adolescent, mother/primary caregivers and family associated factors with mental health service use (N = 1,721).</p

Bivariate analyses showing children/adolescent, mother/primary caregivers and family potential associated factors with mental health service use (N = 1,721).

<p>*2missing;</p><p>**99 missing;</p>#<p>16 missing;</p>§<p>6 missing;</p>¶<p>1 missing;</p>&<p>3missing;</p><p>NA = Not applicable.</p

Structural, psychosocial and demographic characteristics of the sample by site (N = 1,721).

<p>*2 missing;</p><p>**6 missing;</p>#<p>1 missing;</p>§<p>3 missing.</p>⊝<p>chi-square test;</p>£<p>ANOVA test.</p

Observed (unweighted, black) and weighted (IPCW-weighted, gray) annual CD4+ cell counts (median and interquartile range) since start of ART.

<p>Dashed lines represent important CD4+ cell count thresholds of 200, 350, and 500 cells/μL.</p

Observed (unweighted, dots) and weighted (IPCW-weighted, lines) annual median CD4+ cell counts since start of ART stratified by cohort, age at start of ART, gender and race.

<p>Dashed lines represent important CD4+ cell count thresholds of 200, 350, and 500 cells/μL.</p

Column 2: Demographic, behavioral and clinical characteristics of the study population (number [percentages] are given unless otherwise stated); Columns 3 to 8: Results of the logistic regression models for the three outcomes: ART discontinuation, Loss to Follow-up and Initial ART Regimen.

<p>HIV: human immunodeficiency virus, ART: antiretroviral therapy, ADI: AIDS defining illness.</p>a<p>Age at the start of ART.</p>b<p>Reported mode of HIV risk exposure was categorized injection drug users (IDU) and not IDU.</p>c<p>Pre-treatment CD4+ cell count and HIV RNA were defined as the value closest to the date of start of ART up to 6 months prior.</p>d<p>Initial ART regimen was classified as NNRTI-based or PI-based. Integrase inhibitor-based regimens were too few (N = 75) to draw consistent conclusions and were thus excluded.</p>e<p>ADI at the start of ART was defined as the presence of any CDC 1993 condition at six months prior to up to one month after start of ART.</p>f<p>Hepatitis B/C co-infection was defined as having chronic infection at the start of ART.</p>h<p>Significant cohort and ADI interaction term [aOR 2.02 (1.42, 2.86)].</p

Observed (unweighted, dots) and weighted (IPCW-weighted, lines) annual median CD4+ cell counts since start of ART stratified by pre-treatment CD4+ cell count and nadir CD4+ cell count.

<p>Dashed lines represent important CD4+ cell count thresholds of 200, 350, and 500 cells/μL.</p

Unstratified and stratified observed and weighted median (interquartile range) CD4+ cell counts for years 1, 4, 7 and 10 after start of antiretroviral therapy and the percentage of patients with weighted CD4+ cell count >500/μL at year 10.

<p>HIV: human immunodeficiency virus, ART: antiretroviral therapy, ADI: AIDS defining illness.</p>a<p>Age at the start of ART.</p>b<p>Reported mode of HIV risk exposure was categorized injection drug users (IDU) and not IDU.</p>c<p>Pre-treatment CD4+ cell count and HIV RNA were defined as the value closest to the date of start of ART up to 6 months prior.</p>d<p>Initial ART regimen was classified as NNRTI-based or PI-based. Integrase inhibitor-based regimens were too few (N = 75) to draw consistent conclusions and were thus excluded.</p>e<p>ADI at the start of ART was defined as the presence of any CDC 1993 condition at six months prior to up to one month after start of ART.</p>f<p>Hepatitis B/C co-infection was defined as having chronic infection at the start of ART.</p

Observed (unweighted, dots) and weighted (IPCW-weighted, lines) annual median CD4+ cell counts since start of ART stratified by initial ART regimen and pre-treatment HIV RNA viral load.

<p>Dashed lines represent important CD4+ cell count thresholds of 200, 350, and 500 cells/μL.</p

Demographic, behavioral and clinical characteristics at the start of ART for patients followed at the Evandro Chagas Clinical Research Institute (IPEC) and the Johns Hopkins AIDS Services.

<p>HIV: human immunodeficiency virus, ART: antiretroviral therapy, ADI: AIDS defining illness.</p>a<p>Age at the start of ART.</p>b<p>Reported mode of HIV risk exposure was categorized injection drug users (IDU) and not IDU</p>c<p>Pre-treatment CD4+ cell count and HIV RNA were defined as the value closest to the date of start of ART up to 6 months prior.</p>d<p>Initial ART regimen was classified as NNRTI-based or PI-based. Integrase inhibitor-based regimens were too few (N = 75) to draw consistent conclusions and were thus excluded.</p>e<p>Concurrent AIDS defining illness (ADI) was defined as the presence of any CDC 1993 condition at six months prior to up to one month after start of ART</p>f<p>Hepatitis B/C co-infection was defined as having chronic infection at the start of ART.</p